Brendan P. Eckelman's Net Worth
$0
Who is Brendan P. Eckelman?
Brendan P. Eckelman does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Inhibrx, Inc., and Inhibrx Biosciences, Inc..
SEC CIK
Brendan P. Eckelman's CIK is 0001766433
Past Insider Trading and Trends
2021 was Brendan P. Eckelman's most active year for acquiring shares with 1 total transactions. Brendan P. Eckelman's most active month to acquire stocks was the month of December. 2024 was Brendan P. Eckelman's most active year for disposing of shares, totalling 10 transactions. Brendan P. Eckelman's most active month to dispose stocks was the month of February. 2024 saw Brendan P. Eckelman paying a total of $0.00 for 175,000 shares, this is the most they've acquired in one year. In 2024 Brendan P. Eckelman cashed out on 80,000 shares for a total of $1,641,550.02, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Inhibrx, Inc. (INBX) Snapshot price: $15.06
Chief Scientific Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -2.36M |
$30.21 | -$71,956,590.00 |
0
|
May 28 - May 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 8 - Mar 12
| |||
Form 4
| -1.93% | -40.00K |
$24.21 | -$968,230.72 | 2.04M |
Scheduled
|
Mar 1
| ||
Form 4
| -1.89% | -40.00K |
$24.93 | -$997,210.19 | 2.08M |
Scheduled
|
Feb 1 - Feb 2
| ||
Form 4
| -1.86% | -40.00K |
$23.71 | -$948,598.33 | 2.12M |
Scheduled
|
Jan 3 - Jan 4
| ||
Form 4
| -1.82% | -40.00K |
$27.22 | -$1,088,682.75 | 2.16M |
Scheduled
|
Dec 6
| ||
Form 4
| -1.79% | -40.00K |
$33.51 | -$1,340,387.06 | 2.2M |
Scheduled
|
Nov 1
| ||
Form 4
| -1.76% | -40.00K |
$27.82 | -$1,112,813.33 | 2.24M |
Scheduled
|
Oct 4
| ||
Form 4
|
—
|
0
|
—
|
—
| 2.6M |
Sep 13
| |||
Form 4
| -1.62% | -40.00K |
$14.91 | -$596,273.65 | 2.44M |
Scheduled
|
Sep 6
| ||
Form 4
| -1.59% | -40.00K |
$18.00 | -$719,834.55 | 2.48M |
Scheduled
|
Aug 2 - Aug 3
| ||
Form 4
| -1.57% | -40.00K |
$17.17 | -$686,800.00 | 2.52M |
Scheduled
|
Jul 7
| ||
Form 4
| -0.02% | -400.00 |
$25.04 | -$10,016.00 | 2.56M |
Scheduled
|
Apr 5
| ||
Form 4
| -0.66% | -17.00K |
$19.02 | -$323,340.00 | 2.56M |
Scheduled
|
Mar 24
| ||
Form 4
| -0.66% | -17.00K |
$25.90 | -$440,300.00 | 2.57M |
Scheduled
|
Feb 16
| ||
Form 4
|
—
|
0
|
—
|
—
| 2.75M |
Dec 4 - Jan 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Inhibrx Biosciences, Inc. No price found
Chief Scientific Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 513.89K |
—
|
—
| 513.89K |
May 29 - May 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||